HEB Hemispherx BioPharma Inc.

-0.01  -5%
Previous Close 0.21
Open 0.21
Price To Book 1.54
Market Cap 9786064
Shares 48,930,318
Volume 545,931
Short Ratio 1.96
Av. Daily Volume 303,134

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 19609737
  2. 424B4 - Prospectus [Rule 424(b)(4)] 19608530
  3. 8-K - Current report 19582682
  4. 8-K - Current report 19573013
  5. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 19572209

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.

Latest News

  1. Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
  2. Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
  3. Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer
  4. Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
  5. Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference
  6. Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences — Renewed Outlook, Key Drivers of Growth
  7. REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
  8. Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
  9. Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center
  10. Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  11. Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation
  12. Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program
  13. Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States
  14. Hemispherx Biopharma Issues Letter to Stockholders
  15. Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018